Online First
Case Report
Long-term remissions with Gilteritinib in early relapse after allogeneic stem cell transplantation of FLT3/NPM1 mutated acute myeloid leukemia
Keywords
acute myeloid leukemia, post-transplant relapse, FLT3-inhibitors
Submitted:January 27, 2024
Accepted:February 27, 2024
Published online:June 14, 2024
Abstract
Early post-allogeneic hematopoietic stem cell transplantation (allo-HSCT) relapse in patients with acute myeloid leukemia (AML) has an almost invariably dismal prognosis. Recent studies have demonstrated that FLT3 inhibition enhances the graft-versus-leukemia effect in vitro and in vivo. Thus, FLT-3 inhibitors may be viable treatment options in this setting. Here, we report three patients with FLT3 and NPM1 mutated AML who relapsed early after allo-HSCT and were treated with gilteritinib (associated with donor lymphocyte Infusion in two patients) to achieve long-term remission without a second transplantation.
News
![Limited Time Special Offer](https://bct.apbmt.org/wordpress/wp-content/themes/bct/assets/img/BCT_special_offer_square.png?202407160014)
Online ISSN:2432-7026